Baidu
map

Cancer Causes Control:早期前列腺癌男性中婚姻状况与死亡率相关性研究

2019-07-09 AlexYang MedSci原创

最近,有研究人员在一个接受根治性前列腺切除术的早期前列腺癌患者群体中确定了婚姻状态与全因和前列腺癌特异性死亡率之间的关系。研究人员进行了 一个回顾性的群体研究,包括了3579名男性,并利用根治性前列腺切除术进行局部(阶段1-2)前列腺癌的治疗,时间为1999年和2004年之间。研究人员发现,根治性前列下切除术进行时,未婚的婚姻状况与全因死亡率风险的增加(HR 1.42,95%CI 1.10,1.8

最近,有研究人员在一个接受根治性前列腺切除术的早期前列腺癌患者群体中确定了婚姻状态与全因和前列腺癌特异性死亡率之间的关系。

研究人员进行了 一个回顾性的群体研究,包括了3579名男性,并利用根治性前列腺切除术进行局部(阶段1-2)前列腺癌的治疗,时间为1999年和2004年之间。研究人员发现,根治性前列下切除术进行时,未婚的婚姻状况与全因死亡率风险的增加(HR 1.42,95%CI 1.10,1.85)相关。相似的,婚姻历史分析中,没有结婚的男性全因死亡率最高(HR 1.77, 95% CI 1.19, 2.63)。未婚状态同样与前列腺癌特异性死亡率风险的增加相关((HR 1.97; 95% CI 1.01, 3.83)。

最后,研究人员指出,前列腺癌未婚男性在根治性前列腺切除术后死亡风险更高。而已婚前列腺癌男性中婚姻能够对其产生多方面的有利作用,包括了社交支持。进一步的研究需要探明其中的机制,并促进对未婚男性和缺少社交支持的患者的帮助。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-11 dongjia2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-10 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-09 122e052cm96暂无昵称

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1953512, encodeId=f3c41953512a5, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Jul 23 22:48:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837706, encodeId=b723183e706c7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 28 23:48:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569762, encodeId=ff151569e62d1, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jul 11 03:48:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369405, encodeId=f9af36940551, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 10 13:22:16 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369359, encodeId=1735369359a1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Tue Jul 09 16:59:39 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040494, encodeId=b818104049406, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 09 15:48:00 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-09 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Cancer Res:PTEN缺失能够激活NKX3.1降解从而促进前列腺癌恶化

NKX3.1在前列腺癌中是最常见缺失基因和看家抑制子。NKX3.1是一个生长抑制子,能够调节细胞凋亡、诱导抗氧化物产生和DNA修复的加强。PTEN是一个广泛存在的肿瘤抑制因子,在前列腺癌肿瘤恶化期间表达减少。NKX3.1的稳态转变由DYRK1B磷酸化NKX3.1蛋白第185个氨基酸-丝氨酸调控,且能够导致多聚泛素化和蛋白酶体降解。最近,有研究人员表明了PTEN是一个NKX3.1磷酸化酶,能够保护N

NEJM:阿帕鲁胺治疗转移性去势敏感的前列腺癌

研究认为,在雄激素剥夺治疗基础上添加阿伐他胺可显著延长转移性、去势敏感的前列腺癌患者无进展生存率和整体生存期

J Cell Biochem:尿石素B能抑制肝细胞癌肿瘤的生长

已有研究证明,鞣花单宁(ETs)的日常消费有利于多种慢性健康疾病,包括癌症和心血管疾病。尿石素来源于肠道微生物对ETs的代谢,且被认为对上述健康的影响有作用。之前的研究阐释了尿石素在前列腺、乳腺和结肠癌中具有抗增殖的作用。然而,对于肝细胞癌(HCC)的作用仍旧未知。最近,有研究人员评估了尿石素B(UB)在HCC中的功能。研究人员在HCC细胞中调查了UB对细胞存活、细胞周期和凋亡的影响,并发现UB能

BJU Int:前列腺切除术后PSA对抢救性放疗影响研究

最近,有研究人员测试了在根治性前列腺切除术(RP)后,持久性的PSA和PSA在不可检测范围(<0.1ng/ml)内增加时,是否抢救性放疗(SRT)在N0前列腺癌(PCa)中的效果是一样的。研究人员在55名PCa患者中评估了SRT后PSA无进展生存(PFS),并将整个群体与一个风险调整后的包括112名患者的亚群进行了比较,并且具有匹配的RP前PSA(±10ng/ml)、格林森评分(≤6 vs

PLoS One:转移性前列腺恶性肿瘤中的TP53变异分析

测序数据在鉴定前列腺恶性肿瘤的致瘤驱使因子方面是有帮助的,并且能够鉴定确定恶性疾病的生物标记。最近,有研究人员对30个原发性和转移性前列腺恶性肿瘤案例的测序结果进行了回顾,并鉴定了TP53基因的常见结构变异情况。研究发现,这些结构变异在27%的测序案例中发现,并代表了转移性疾病36%的案例。TP53结构重排之前在骨肉瘤中具有报道,其重排结果导致了p53蛋白表达的缺失。相似地,在他们研究中,TP53

J Urol:前列腺癌男性患者中循环肿瘤细胞的鉴定和分析

大约15%新诊断的前列腺癌男性具有高风险特性,这些特性能够增加复发和转移的风险。更好的预测生物标记可以进行生化复发(BCR)的检测、调整监控措施和辅助治疗方式。循环肿瘤细胞(CTCs)代表了转移的最早形式,然而它们在高风险局部前列腺癌(HRLPCa)男性中作为生物标记还没有很好的鉴定。研究人员从37名经历前列腺切术术后2-5个月的HRLPCa患者中抽取了血液样本。研究发现,在81.1%(30/37

Baidu
map
Baidu
map
Baidu
map